DHR - Danaher Corporation
A scientific instrument and diagnostics conglomerate whose portfolio of precision tools is essential to pharmaceutical manufacturing, life sciences, and environmental testing.
Finlify Score
32.3 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$200.14
-0.19%
52W Range
$160.93 - $242.80
Market Cap
$150.1B
-0.2%Compared to previous day
2026 Q1 Revenue
$6.0B
-13.0%Changes from last reporting quarter
2026 Q1 EPS
$1.00
Diluted shares
Analyst Rating
32 analysts in latest ratings feed
RSI
18.9
<40 oversold
2Y Range Position
33%
-28.5% from high / +24.4% from low
Beta
0.80
Relative to market benchmark
MACD
-2.09
MACD line 0.40 / signal line 2.49
Fundamental Trend
Growth 13.1Financial Health
Quality 78.5Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID32.3 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $6.0B-13.0% | $6.8B+13.0% | $6.1B+2.0% | $5.9B+3.4% |
| Gross Profit | $3.6B-9.5% | $4.0B+12.6% | $3.5B0.0% | $3.5B+0.3% |
| Operating Income | $1.3B-10.5% | $1.5B+30.2% | $1.2B+51.8% | $760M-40.3% |
| Net Income | $1.0B-14.0% | $1.2B+31.8% | $908M+63.6% | $555M-41.8% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Aug 1, 2026
Finlify's signal for DHR is AVOID, with a Finlify Score of 43.0 out of 100. This appears to be primarily driven by very low Relative Strength and Fundamental Trend scores, despite strong Accumulation/Volume and solid Financial Quality.
Technical
The asset's Relative Strength score of 17.2/100 suggests significant underperformance compared to its peers. Despite this, the Accumulation / Volume score is very high at 97.0/100, indicating strong buying interest on volume. DHR is currently trading 19.0% below its 52-week high, and its 60-day return stands at 12.7%.
Fundamentals
The Fundamental Trend score is notably low at 13.1/100, which may indicate deteriorating fundamental prospects, even though the Financial Quality score is a robust 78.5/100. Valuation metrics appear elevated, with a P/E ratio of 38.1x and a P/S ratio of 5.6x. The asset offers a modest dividend yield of 0.82% and has a beta of 0.8, suggesting lower volatility than the broader market.
Macro Context
The prevailing macro environment, characterized by elevated inflation indicators such as CPI YoY at 3.7% and Core PCE YoY at 3.3%, along with a 10Y Treasury Yield of 4.7%, suggests a higher interest rate environment. This could potentially exert pressure on growth-oriented companies like DHR, especially given its current valuation multiples.
Key Risks
- The very low Fundamental Trend score of 13.1/100 suggests potential underlying fundamental deterioration or a negative outlook, which could be a significant headwind.
- DHR's valuation, with a P/E of 38.1x and P/S of 5.6x, appears elevated, which may make it vulnerable in a higher interest rate environment or if future growth expectations are not met.
- A Relative Strength score of 17.2/100 indicates that the asset has been significantly underperforming its peers, potentially signaling a lack of investor confidence or structural challenges.